Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: Potential biomarkers for a more favorable prognosis?

Journal of Immunotoxicology

Volumn 10, Issue 4, 2013, Pages 380-386

  Hammad, Lamiaa N ^a   Abdelraouf, Sahar M ^a   Hassanein, Fetouh S ^b   Mohamed, Walid A ^c   Schaalan, Mona F ^a  

^a Biochemistry Department   (Serbia)

^b Egypt   (Egypt)

^c Cairo General Hospital   (Egypt)

Author keywords

HCC; HCV; IL 17; IL 6; Vitamin D

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; INTERLEUKIN 17; INTERLEUKIN 6; VIRUS RNA; VITAMIN D;

ADULT; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKIN-17; INTERLEUKIN-6; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RNA, VIRAL; TUMOR MARKERS, BIOLOGICAL; VIRAL LOAD; VITAMIN D;

EID: 84879513296     PISSN: 1547691X     EISSN: None     Source Type: Journal    
DOI: 10.3109/1547691X.2012.758198     Document Type: Article

References (61)

1. Abdel-Wahab, M., Mostafa, M., Sabry, M., et al. 2008. Aflatoxins as a risk factor for hepatocellular carcinoma in Egypt: Mansoura Gastroenterology Center study. Hepatogastroenterology 55:1754-1759.
2. Abu Mouch, S., Fireman, Z., Jarchovsky, J., and Assy, N. 2010. Vitamin D supplement improve SVR in chronic hepatitis C (genotype I) naive patients treated with PEG, interferon, and ribavirin. 45th Annual Meeting of European Association for Study of the Liver (EASL 2010). Vienna, Austria.
3. Abu Mouch, S., Fireman, Z., Jarchovsky, J., et al. 2011. Vitamin D supplement improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J. Gastroenterol. 17:5184-5190.
4. Ataseven, H., Bahcecioglu, I. H., Kuzu, N., et al. 2006. The levels of ghrelin, leptin. TNFα, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection. Mediat. Inflamm. 4:78380.
5. Babbs, C., Smith, A., Hunt, L. P., et al. 1988. Type III pro-collagen peptide: A marker activity and prognosis in primary biliary cirrhosis. Lancet 1:1021-1024.
6. Bertino, G., Neri, S., Bruno, C. M., et al. 2011. Diagnostic and prognostic value of α-fetoprotein, des-γ-carboxy-prothrombin, and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med. 102:363-371.
7. Bialecki, E. S., and Di Bisceglie, A. M. 2005. Clinical presentation and natural course of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 17:485-489.
8. Caldwell, C. C., Okaya, T., Martignoni, A., et al. 2005. Divergent functions of CD4 T-lymphocytes in acute liver inflammation and injury after ischemia-reperfusion. Am. J. Physiol. 289:G969-976.
9. Chan, S. L., Mo, F. K., Wong, C. S., et al. 2012. A study of circulating IL-10 in prognostication of un-resectable hepatocellular carcinoma. Cancer 118:3984-3992.
10. H17 polarization and IL-22 expression by memory T-cells from patients with early rheumatoid arthritis. Arthritis Rheum. 62:132-142.
11. Deluca, H. F., and Cantorna, M. T. 2001. Vitamin D: Its role and uses in immunology. FASEB J. 15:2579-2585.
12. Denning, T. L., Wang, Y. C., Patel, S. R., et al. 2007. Lamina propria macrophages and dendritic cells differentially induce regulatory and IL-17-producing T-cell responses. Nat. Immunol. 8:1086-1094.
13. Durazo, F. A., Blatt, L. M., Corey, W. G., et al. 2008. Desγ-carboxyprothrombin, α-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. J. Gastroenterol. Hepatol. 23:1541-1548.
14. El-Houseini, M. E., Mohammed, M. S., Elshemey, W. M., et al. 2005. Enhanced detection of hepatocellular carcinoma. Cancer Control 12:248-253.
15. El Husseiny, N. M., Fahmy, H. M., Mohamed, W. A., and Amin, H. H. 2012. Relationship between vitamin D and IL-23, IL-17, and MCP-1 as markers of fibrosis in hepatitis C+ Egyptians. World J. Hepatol. 4:242-247.
16. Elnemr, D. M., Abdel-Azeez, H. A., Labib, H. A., and Abo-Taleb, F. M. 2012. Clinical relevance of serum endoglin level in Egyptian hepatocellular carcinoma patients. Clin. Lab. 58:1023-1028.
17. Elsharkawy, A. M., and Mann, D. A. 2007. Nuclear factor-κB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46:590-597.
18. Falasca, K., Ucciferri, C., Dalessandro, M., et al. 2006. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann. Clin. Lab. Sci. 36:144-150.
19. Fathy, A., Ahmed, A. S., Metwally, L., and Hassan, A. 2011. T-Helper Type 1/T-helper Type 17-related cytokines in chronic Hepatitis C patients before and after interferon and ribavirin therapy. Med. Princ. Pract. 20:345-349.
20. Fisher, L., and Fisher, A. 2007. Vitamin D and parathyroid hormone in outpatients with non-cholestatic chronic liver disease. Clin. Gastroenterol. Hepatol. 5:513-520.
21. Giardina, M. G., Matarazzo, M., Varriale, A., et al. 1992. Serum α-Lfucosidase. A useful marker in the diagnosis of hepatocellular carcinoma. Cancer 70:1044-1048.
22. Heninger, E., Hogan, L. H., Karman, J., et al. 2006. Characterization of the Histoplasma capsulatum-induced granuloma. J. Immunol. 177:3303-3313.
23. Holick, M. F., and Chen, T. C. 2008. Vitamin D deficiency: A worldwide problem with health consequences. Am. J. Clin. Nutr. 87:1080S-1086S.
24. Hollis, B. W. 1986. Assay of circulating 1,25-dihydroxy Vitamin D involving a novel single-cartridge extraction and purification procedure. Clin. Chem. 32:2060-2063.
25. Hsia, C. Y., Huo, T. I., Chiang, S. Y., et al. 2007. Evaluation of IL-6, IL-10, and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur. J. Surg. Oncol. 33:208-212.
26. H17, and pro-fibrotic responses in hepatitis C-infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin. Eur. Cytokine Network 21:84-91.
27. Johnson, P. J. 2001. The role of serum α-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin. Liver Dis. 5:145-159.
28. Kamal, S. M., and Nasser, I. A. 2008. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology 47:1371-1383.
29. H17 cells. Annu. Rev. Immunol. 27:485-517.
30. H17 mediators and vitamin D status. Crit. Care 14:410.
31. Lange, C. M., Bojunga, J., Ramos-Lopez, E., et al. 2011. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to IFNα-based therapy. J. Hepatol. 54:887-893.
32. Lange, N. E., Litonjua, A., Hawrylowicz, C. M., and Weiss, S. 2009. Vitamin D, the immune system, and asthma. Expert Rev. Clin. Immunol. 5:693-702.
33. Lee, Y., Park, U. S., Choi, I., et al. 1998. Human IL-6 gene is activated by hepatitis B virus-X protein in human hepatoma cells. Clin. Cancer Res. 4:1711-1717.
34. Lehman, E. M., and Wilson, M. L. 2009. Epidemic hepatitis C virus infection in Egypt: Estimates of past incidence and future morbidity and mortality. J. Viral Hepat. 16:650-658.
35. Lemmers, A., Moreno, C., Gustot, T., et al. 2009. The IL-17 pathway is involved in human alcoholic liver disease. Hepatology 49:646-657.
36. + T-cells. J. Cell. Biochem. 89:922-932.
37. Mawer, E. B. 1980. Clinical implications of measurements of circulating vitamin D metabolites. Clin. Endocrinol. Metab. 9:63-79.
38. Mohran, Z. Y., Ali-Eldin, F. A., and Abdel Aal, H. A. 2011. Serum IL-18: Does it have a role in diagnosis of hepatitis C virus-related hepatocellular carcinoma? Arab J. Gastroenterol. 12:29-33.
39. Muller, K., Svenson, M., and Bendtzen, K. 1988. 1α,25- Dihydroxyvitamin D3 and a novel vitamin D analogue MC903 are potent inhibitors of human IL-1 in vitro. Immunol. Lett. 17:361-365.
40. Petta, S., Cammà, C., Scazzone, C., et al. 2010. Low Vitamin D serum level is related to severe fibrosis and low responsiveness to IFN-based therapy in genotype I chronic hepatitis C. Hepatology 51:1158-1167.
41. Porta, C., De Amici, M., Quaglini, S., et al. 2008. Circulating IL-6 as a tumor marker for hepatocellular carcinoma. Ann. Oncol. 19:353-358.
42. Rutitzky, L. I., Bazzone, L., Shainheit, M. G., et al. 2008. IL-23 is required for the development of severe egg-induced immunopathology in schistosomiasis and for lesional expression of IL-17. J. Immunol. 180:2486-2495.
43. Schaalan, M. F., Mohamed, W. A., and Amin, H. H. 2012. Vitamin D deficiency: Correlation to IL-17, IL-23, and PIIINP in hepatitis C virus genotype 420. World J. Gastroenterol. 18:3738-3744.
44. Scott, J. D., and Gretch, D. R. 2007. Molecular diagnostics of hepatitis C virus infection: A systematic review. JAMA 297:724-732.
45. Shimizu, A., Shiraki, K., Ito, T., et al. 2002. Sequential fluctuation pattern of serum des-g-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis. Int. J. Mol. Med. 9:245-250.
46. 3 induces CCR10 expression in terminally differentiating human B-cells. J. Immunol. 180:2786-2795.
47. Soliman, A. S., Hung, C. W., Tsodikov, A., et al. 2010. Epidemiologic risk factors of hepatocellular carcinoma in a rural region of Egypt. Hepatol. Int. 4:681-690.
48. Soresi, M., Giannitrapani, L., D'Antona, F., et al. 2006. IL-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J. Gastroenterol. 12:2563-2568.
49. Spadaro, A., Ajello, A., Luigiano, C., et al. 2006. Low utility of plasma nociceptin/orphanin FQ in the diagnosis of hepatocellular carcinoma. World J. Gastroenterol. 12:4716-4720.
50. Steib, C. J., Gerbes, A. L., Bystron, M., et al. 2007. Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A2. J. Hepatol. 47:228-238.
51. Tai, W. C., Hu, T. H., Wang, J. H., et al. 2009. Clinical implications of α-fetoprotein in chronic hepatitis C. J. Formosa Med. Assoc. 108:210-218.
52. Wang, L., Chen, S., and Xu, K. 2011. IL-17 expression is correlated with hepatitis B-related liver diseases and fibrosis. Int. J. Mol. Med. 27:385-392.
53. H17 cells in peripheral blood correlates with the development of hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi. 32:757-761.
54. Weaver, C. T., Hatton, R. D., Mangan, P. R., and Harrington, L. E. 2007. IL-17 family cytokines and the expanding diversity of effector T-cell lineages. Annu. Rev. Immunol. 25:821-852.
55. Welling, T. H., Fu, S., Wan, S., et al. 2012. Elevated serum IL-8 is associated with presence of hepatocellular carcinoma and independently predicts survival. Cancer Invest. 30:689-697.
56. Yasumi, Y., Takikawa, Y., Endo, R., and Suzuki, K. 2007. Interleukin-17 as a new marker of severity of acute hepatic injury. Hepatol. Res. 37:248-254.
57. Yen, D., Cheung, J., Scheerens, H., et al. 2006. IL-23 is essential for T-cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116:1310-1316.
58. Zhang, J. P., Yan, J., Xu, J., et al. 2009. Increased intra-tumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J. Hepatol. 50:980-989.
59. + T-cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 51:81-91.
60. Zhao, L., Tang, Y., You, Z., et al. 2011. IL-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic IL-6 expression. PLoS One 6:e18909.
61. Zhou, L., Liu, J., and Luo, F. 2006. Serum tumor markers for detection of hepatocellular carcinoma. World J. Gastroenterol. 12:1175-1181.